{"classes":[{"categories":[{"measurements":[{"comment":"Data not available due to high censoring.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Data not available due to high censoring.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"88"}],"units":"Participants"}],"description":"Time to CNS Progression per RECIST 1.1 by BICR (with or without Pembrolizumab)","dispersionType":"95% Confidence Interval","groups":[{"description":"160 mg Selpercatinib administered orally BID continuously in 21-day cycles.","id":"OG000","title":"Selpercatinib (TRT A)"},{"description":"Pemetrexed 500 mg/m2, IV on Day 1 Q3W plus investigator's choice of carboplatin AUC 5 (maximum dose 750 mg) IV or cisplatin 75mg/m2, IV on Day 1 Q3W for 4 cycles, plus investigator's choice with or without 200 mg pembrolizumab IV on Day 1 Q3W up to 35 cycles.","id":"OG001","title":"Pemetrexed and Platinum With or Without Pembrolizumab (TRT B)"}],"paramType":"MEDIAN","populationDescription":"CNS Overall: All participants included in the ITT population who had baseline CNS assessment and who had CNS metastasis at baseline. Participants censored: TRT A: 137; TRT B: = 73.","reportingStatus":"POSTED","timeFrame":"Baseline through CNS Progression or Death Up to 31 Months","title":"Median Time to CNS Progression Per RECIST 1.1 by BICR (With or Without Pembrolizumab)","type":"SECONDARY","unitOfMeasure":"Months"}